KLKB1 Inhibitors Market to Reach New Heights by 2034 Owing to the Launch of Novel Therapies | DelveInsight
The outlook for the KLKB1 inhibitors market is increasingly positive, driven by growing recognition of the kallikrein-kinin pathway's pivotal role in inflammatory, cardiovascular, and rare disease mechanisms. Recent product approvals, such as TAKHZYRO, EKTERLY, KALBITOR, ORLADEYO, and DAWNZTERA, along with emerging therapies such as Lonvoguran ziclumeran (Intellia Therapeutics), Navenibart (Astria Therapeutics), RZ402 (Rezolute), and others, […]